



Colorado Department of Health Care Policy and Financing Preferred Drug List (PDL)

Effective October 1, 2014

PA Forms: available online at <https://www.colorado.gov/hcpf/provider-forms>

The PDL applies to Medicaid fee-for-service members. It does not apply to members enrolled in Rocky Mountain Health HMO or Denver Health Medicaid Choice.

Brand Name Required = BNR
Prior Authorization = PA

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
ALZHEIMER'S AGENTS <i>Effective 4/1/2014</i>	No PA Required (*Must meet eligibility criteria) generic donepezil tab donepezil ODT generic galantamine generic galantamine ER NAMENDA IR	PA Required ARICEPT (donepezil) ARICEPT 23mg (donepezil) ARICEPT ODT (donepezil) EXELON (rivastigmine) (cap, soln. and patch) RAZADYNE (galantamine) RAZADYNE ER (galantamine) NAMENDA XR (memantine)	*eligibility criteria for Preferred Agents – All preferred products will be approved without PA if the member has a diagnosis of dementia which can be verified by SMART PA. Non-preferred products will be approved if the member has failed treatment with one of the preferred products in the last 12 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) Members currently stabilized on a non-preferred product can receive approval to continue on that agent for one year if medically necessary and if there is a diagnosis of dementia.
ANTICOAGULANTS- ORAL <i>Effective 10/1/2014</i>	No PA Required warfarin *XARELTO (rivaroxaban) (2nd line)	PA Required COUMADIN (warfarin) ELIQUIS (apixaban) PRADAXA (dabigatran)	ELIQUIS will be approved if: <ul style="list-style-type: none"> • The member has a diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE) OR • The member is need of prophylaxis for DVT following knee or hip replacement surgery OR • The member has a diagnosis of non-valvular atrial fibrillation AND • The member does not have a mechanical prosthetic heart valve AND • The member does not have an active pathological bleed AND

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			<ul style="list-style-type: none"> • The member has failed warfarin or is not a candidate for warfarin as defined as meeting one of the following criteria: <ul style="list-style-type: none"> ○ The member has a labile INR for reasons other than noncompliance (e.g, member has an INR outside of 2-3 > 60% of the time for a period of two months) OR ○ The member has significant difficulty with complying with monitoring OR ○ The member is on dialysis ○ The member has an allergy or intolerance to warfarin AND • The member has failed a one month trial of Xarelto®. (Failure is defined as : lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) <p>PRADAXA will be approved if:</p> <ul style="list-style-type: none"> • The member is not on dialysis AND • The member has a diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE) OR • The member has a diagnosis of non-valvular atrial fibrillation AND • The member does not have a mechanical prosthetic heart valve AND • The member does not have an active pathological bleed AND • The member has failed warfarin or is not a candidate for warfarin as defined as meeting one of the following criteria: <ul style="list-style-type: none"> ○ The member has a labile INR for reasons other than noncompliance (e.g, member has an INR outside of 2-3 > 60% of the time for a period of two months) OR ○ The member has significant difficulty with complying with monitoring OR ○ The member has an allergy or intolerance to warfarin AND • The member has failed a one month trial of Xarelto®. (Failure is defined as : lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) <p>*XARELTO® will be approved if all the following criteria have been met:</p> <ul style="list-style-type: none"> • The member is not on dialysis AND
--	--	--	---

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
			<ul style="list-style-type: none"> • The member has a diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE) OR • The member is in need of a prophylaxis of DVT following knee or hip replacement surgery OR • The member has a diagnosis of non-valvular atrial fibrillation AND • The member does not have a mechanical prosthetic heart valve AND • The member does not have an active pathological bleed AND • The member has failed warfarin or is not a candidate for warfarin as defined as meeting one of the following criteria: <ul style="list-style-type: none"> ○ Labile INR for reasons other than noncompliance (e.g, member has an INR outside of 2-3 > 60% of the time for a period of two months) OR ○ The member has significant difficulty with complying with monitoring OR ○ The member has an allergy or intolerance to warfarin <p>Grandfathering: Beginning 10/1/2013, members currently stabilized on a non-preferred agent can receive approval to continue on that agent for one year if medically necessary</p>
ANTI-EMETICS <i>Effective 1/1/2014</i>	No PA Required ondansetron tablets ondansetron ODT tab ondansetron suspension (members under 5 years only) ZOFRAN tablets	PA Required ALOXI (palonosetron) ANZEMET (dolasetron) DICLEGIS (doxylamine/pyridoxine) EMEND (aprepitant) KYTRIL (granisetron) SANCUSO (granisetron)	Non-preferred products will be approved for members who have failed treatment with brand or generic ondansetron within the last year. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.) Ondansetron suspension will be approved for member's ≥ 5 years old and with a feeding tube. Emend will be approved upon verification that the member is undergoing moderately emetogenic or highly emetogenic chemotherapy as part of a regimen with a corticosteroid and a 5HT3 antagonist. Verification may be provided from the prescriber or the pharmacy. Emend will be approved for prophylaxis of postoperative nausea and vomiting (one 40mg capsule will be approved). Verification may be provided from the prescriber or the pharmacy. Approval for DICLEGIS will be granted if the member has nausea and vomiting associated with pregnancy AND

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	---

		ZOFRAN (ondansetron) suspension ZOFRAN ODT (ondansetron) ZUPLLENZ (ondansetron)	The member has failed a trial of doxylamine 10-12.5mg OR The member has failed a trial of oral ondansetron 4mg every 8 hours for five days OR The member has an intolerance or contraindication to ondansetron
ANTI-DEPRESSANTS Newer Generation Antidepressants <i>Effective 1/1/2014</i>	No PA Required bupropion IR, SR, XL citalopram fluoxetine fluvoxamine mirtazipine nefazodone paroxetine sertraline venlafaxine IR tabs venlafaxine XR capsules	PA Required APLENZIN ER (bupropion ER) BRINTELLIX (vortioxetine) CYMBALTA (duloxetine) FETZIMA (levomilnacipran) KHEDEZLA (desvenlafaxine base) LEXAPRO (escitalopram) LUVOX CR (fluvoxamine CR) PRISTIQ (desvenlafaxine succinate) PEXEVA (paroxetine) paroxetine CR PAXIL CR (paroxetine controlled release) PROZAC Weekly (fluoxetine) VIIBRYD (vilazodone)	Non-preferred products will be approved for members who have failed treatment with three Preferred Products with exceptions for Cymbalta and Lexapro (see below). (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) Grandfathering: Members currently stabilized on a Non-preferred newer generation antidepressant can receive approval to continue on that agent for one year if medically necessary. Verification may be provided from the prescriber or the pharmacy. Cymbalta: Members will not need to fail on three Preferred Products if the diagnosis is Diabetic Peripheral Neuropathic Pain. Cymbalta will also be approved for patients with chronic musculoskeletal pain (e.g. osteoarthritis or chronic lower back pain) who have failed a one month consecutive trial of three non-narcotic analgesic agents (e.g. acetaminophen, NSAID, tramadol) at maximally tolerated doses. Lexapro: Members will not need to fail on three Preferred Products if they are under 18 years of age and have failed therapy with fluoxetine. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.)
ANTI-HERPETIC AGENTS <i>Effective 1/1/2014</i>	No PA Required acyclovir tablet, capsule (generic)	PA Required acyclovir suspension	Non-preferred products will be approved for members who have failed an adequate trial with acyclovir (dose and duration) as deemed by approved compendium (see below) (Failure is defined as: lack of

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

		FAMVIR (famciclovir) famciclovir SITAVIG (acyclovir) VALTREX (valacyclovir) valacyclovir ZOVIRAX (acyclovir)	<p>efficacy, allergy, intolerable side effects, or significant drug-drug interaction)</p> <table border="1"> <thead> <tr> <th data-bbox="1241 326 1461 358">Indication</th> <th data-bbox="1461 326 1715 358">Adult</th> <th data-bbox="1715 326 2030 358">Pediatric</th> </tr> </thead> <tbody> <tr> <td data-bbox="1241 358 1461 524">Genital herpes simplex: Initial</td> <td data-bbox="1461 358 1715 524">400 mg orally 3 times daily for 7 to 10 days or 200 mg orally 5 times daily (guideline dosing) for 10 days.</td> <td data-bbox="1715 358 2030 524">12 years or older, 1000 to 1200 mg/day orally in 3 to 5 divided doses for 7 to 10 days.</td> </tr> <tr> <td data-bbox="1241 524 1461 883">Genital herpes simplex: episodic</td> <td data-bbox="1461 524 1715 883">400 mg orally 3 times daily for 5 days or 800 mg orally twice daily for 5 days or 800 mg orally 3 times daily for 2 days (guideline dosing); or 200 mg orally every 4 hours, 5 times daily for 5 days; initiate at earliest sign or symptom of recurrence.</td> <td data-bbox="1715 524 2030 883">12 years or older, 1000 to 1200 mg/day orally in 3 divided doses for 3 to 5 days</td> </tr> <tr> <td data-bbox="1241 883 1461 1049">Genital herpes simplex: Suppressive</td> <td data-bbox="1461 883 1715 1049">400 mg orally twice daily for up to 12 months; alternative dosing, 200 mg orally 3 to 5 times daily.</td> <td data-bbox="1715 883 2030 1049">12 years or older, 800 to 1200 mg/day orally in 2 divided doses for up to 12 months</td> </tr> <tr> <td data-bbox="1241 1049 1461 1385">Genital Herpes Simplex with HIV infection: Initial or Recurrent</td> <td data-bbox="1461 1049 1715 1385">400 mg ORALLY 3 times daily for 5 to 14 days</td> <td data-bbox="1715 1049 2030 1385"> < 45 kg: 20 mg/kg (MAX, 800 mg) ORALLY 4 times daily for 7 to 10 days or until no new lesions appear for 48 hours. Adolescents: 400 mg ORALLY twice daily for 5 to 14 days. </td> </tr> </tbody> </table>	Indication	Adult	Pediatric	Genital herpes simplex: Initial	400 mg orally 3 times daily for 7 to 10 days or 200 mg orally 5 times daily (guideline dosing) for 10 days.	12 years or older, 1000 to 1200 mg/day orally in 3 to 5 divided doses for 7 to 10 days.	Genital herpes simplex: episodic	400 mg orally 3 times daily for 5 days or 800 mg orally twice daily for 5 days or 800 mg orally 3 times daily for 2 days (guideline dosing); or 200 mg orally every 4 hours, 5 times daily for 5 days; initiate at earliest sign or symptom of recurrence.	12 years or older, 1000 to 1200 mg/day orally in 3 divided doses for 3 to 5 days	Genital herpes simplex: Suppressive	400 mg orally twice daily for up to 12 months; alternative dosing, 200 mg orally 3 to 5 times daily.	12 years or older, 800 to 1200 mg/day orally in 2 divided doses for up to 12 months	Genital Herpes Simplex with HIV infection: Initial or Recurrent	400 mg ORALLY 3 times daily for 5 to 14 days	< 45 kg: 20 mg/kg (MAX, 800 mg) ORALLY 4 times daily for 7 to 10 days or until no new lesions appear for 48 hours. Adolescents: 400 mg ORALLY twice daily for 5 to 14 days.
Indication	Adult	Pediatric																
Genital herpes simplex: Initial	400 mg orally 3 times daily for 7 to 10 days or 200 mg orally 5 times daily (guideline dosing) for 10 days.	12 years or older, 1000 to 1200 mg/day orally in 3 to 5 divided doses for 7 to 10 days.																
Genital herpes simplex: episodic	400 mg orally 3 times daily for 5 days or 800 mg orally twice daily for 5 days or 800 mg orally 3 times daily for 2 days (guideline dosing); or 200 mg orally every 4 hours, 5 times daily for 5 days; initiate at earliest sign or symptom of recurrence.	12 years or older, 1000 to 1200 mg/day orally in 3 divided doses for 3 to 5 days																
Genital herpes simplex: Suppressive	400 mg orally twice daily for up to 12 months; alternative dosing, 200 mg orally 3 to 5 times daily.	12 years or older, 800 to 1200 mg/day orally in 2 divided doses for up to 12 months																
Genital Herpes Simplex with HIV infection: Initial or Recurrent	400 mg ORALLY 3 times daily for 5 to 14 days	< 45 kg: 20 mg/kg (MAX, 800 mg) ORALLY 4 times daily for 7 to 10 days or until no new lesions appear for 48 hours. Adolescents: 400 mg ORALLY twice daily for 5 to 14 days.																

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			<table border="1"> <tr> <td data-bbox="1247 235 1461 397">Genital Herpes Simplex with HIV infection: Chronic suppression</td> <td data-bbox="1461 235 1715 397">400 mg orally twice daily</td> <td data-bbox="1715 235 2026 397"></td> </tr> <tr> <td data-bbox="1247 397 1461 483">Herpes labialis</td> <td data-bbox="1461 397 1715 483">400 mg orally 3 times daily for 5 to 10 days</td> <td data-bbox="1715 397 2026 483"></td> </tr> <tr> <td data-bbox="1247 483 1461 570">Herpes zoster, Shingles</td> <td data-bbox="1461 483 1715 570">800 mg orally every 4 hours 5 times a day for 7 to 10 days</td> <td data-bbox="1715 483 2026 570"></td> </tr> <tr> <td data-bbox="1247 570 1461 680">Herpes Zoster, Shingles with HIV infection</td> <td data-bbox="1461 570 1715 680">800 mg orally 5 times daily for 7 to 10 days</td> <td data-bbox="1715 570 2026 680"></td> </tr> <tr> <td data-bbox="1247 680 1461 821">Varicella</td> <td data-bbox="1461 680 1715 821">800 mg orally 4 times a day for 5 days</td> <td data-bbox="1715 680 2026 821">2 years or older: 20 mg/kg ORALLY 4 times a day for 5 days; over 40 kg, 800 mg ORALLY 4 times a day for 5 days</td> </tr> <tr> <td data-bbox="1247 821 1461 976">Varicella with HIV infection</td> <td data-bbox="1461 821 1715 976">20 mg/kg (MAX, 800 mg) ORALLY 5 times daily for 5 to 7 days</td> <td data-bbox="1715 821 2026 976">20 mg/kg (MAX, 800 mg) ORALLY 4 times daily for 7 to 10 days or until no new lesions appear for 48 hours.</td> </tr> </table>	Genital Herpes Simplex with HIV infection: Chronic suppression	400 mg orally twice daily		Herpes labialis	400 mg orally 3 times daily for 5 to 10 days		Herpes zoster, Shingles	800 mg orally every 4 hours 5 times a day for 7 to 10 days		Herpes Zoster, Shingles with HIV infection	800 mg orally 5 times daily for 7 to 10 days		Varicella	800 mg orally 4 times a day for 5 days	2 years or older: 20 mg/kg ORALLY 4 times a day for 5 days; over 40 kg, 800 mg ORALLY 4 times a day for 5 days	Varicella with HIV infection	20 mg/kg (MAX, 800 mg) ORALLY 5 times daily for 5 to 7 days	20 mg/kg (MAX, 800 mg) ORALLY 4 times daily for 7 to 10 days or until no new lesions appear for 48 hours.
Genital Herpes Simplex with HIV infection: Chronic suppression	400 mg orally twice daily																				
Herpes labialis	400 mg orally 3 times daily for 5 to 10 days																				
Herpes zoster, Shingles	800 mg orally every 4 hours 5 times a day for 7 to 10 days																				
Herpes Zoster, Shingles with HIV infection	800 mg orally 5 times daily for 7 to 10 days																				
Varicella	800 mg orally 4 times a day for 5 days	2 years or older: 20 mg/kg ORALLY 4 times a day for 5 days; over 40 kg, 800 mg ORALLY 4 times a day for 5 days																			
Varicella with HIV infection	20 mg/kg (MAX, 800 mg) ORALLY 5 times daily for 5 to 7 days	20 mg/kg (MAX, 800 mg) ORALLY 4 times daily for 7 to 10 days or until no new lesions appear for 48 hours.																			
ANTI-HISTAMINES Newer Generation Antihistamines <i>Effective 7/1/2014</i>	No PA Required cetirizine (generic OTC Zyrtec) loratadine (generic OTC Claritin)	PA Required ALLEGRA (fexofenadine) CLARINEX (desloratadine) CLARITIN (loratadine) fexofenadine (generic Allegra) levocetirizine XYZAL (levocetirizine) ZYRTEC (cetirizine) Brand	Non-preferred antihistamines and antihistamine/decongestant combinations will be approved for members who have failed treatment with two preferred products in the last 6 months and have at least one trial with intranasal corticosteroids (for children age 4 and older). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.)																		

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
Antihistamine/Decongestant Combinations <i>Effective 7/1/2014</i>	No PA Required	PA Required ALLEGRA-D (fexofenadine./PSE) CLARINEX-D (desloratadineD) CLARITIN-D (loratadine-D) loratadine-D SEMPREX-D (acrivastine-D) ZYRTEC-D (cetirizine-D)	
ANTI-HYPERTENSIVES Angiotensin Receptor Blockers (ARBs) <i>Effective 7/1/2014</i>	No PA Required BENICAR (olmesartan) DIOVAN ^{BNR} (valsartan) irbesartan losartan	PA Required ATACAND (candesartan) AVAPRO (irbesartan) brand COZAAR (losartan) EDARBI (azilsartan) MICARDIS (telmisartan) TEVETEN (eprosartan) Valsartan	Non-preferred ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products will be approved for members who have failed treatment with three preferred products in the last 12 months (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.). Tekturna®, Tekturna HCT®, Valutrna®, and Amturnide® will not be approved in patients with diabetes. Receiving an ACE-inhibitor, ACE-inhibitor combination, ARB, or ARB-combination in combination with a renin inhibitor is contraindicated. Grandfathering: Members currently stabilized on brand name Avapro or Avalide can receive approval to continue on that agent for one year if medically necessary. Verification may be provided from the prescriber or the pharmacy.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

ARB Combinations <i>Effective 7/1/2014</i>	No PA Required BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT ^{BNR} (valsartan/HCTZ) losartan/HCTZ	PA Required ATACAND-HCT (candesartan/HCTZ) AVALIDE (irbesartan/HCTZ) AZOR(amlodipine/olmesartan) EXFORGE (amlodipine/valsartan) EXFORGE HCT (amlodipine/valsartan/hctz) Hyzaar HCT (losartan/hctz) irbesartan/HCTZ MICARDIS-HCT (telmisartan/HCTZ) TEVETEN-HCT (eprosartan/HCTZ) TRIBENZOR (olmesartan/amlodipine/hctz) TWYNSTA (telmisartan/amlodipine) VALTURNA (aliskiren/valsartan) valsartan/HCTZ	
--	---	--	--

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	---

Renin Inhibitors & Renin Inhibitor Combinations <i>Effective 7/1/2014</i>	No PA Required	PA Required AMTURNIDE (aliskirin/amlodipine/HCTZ) TEKAMLO (aliskiren/amlodipine) TEKTURNA (aliskiren) TEKTURNA HCT (aliskiren/HCTZ) VALTURNA (aliskiren/valsartan)	
ANTI-PLATELETS <i>Effective 1/1/2014</i>	No PA Required AGGRENOX (ASA/dipyridamole) clopidogrel EFFIENT (prasugrel) Ticlopidine	PA Required BRILINTA (tigacrelor) PLAVIX (clopidogrel) TICLID (ticlopidine) ZONTIVITY (vorapaxar)	EFFIENT 10mg should only be considered for patients < 75 years of age and patients weighing ≥ 60 kg without a known diagnosis of TIA or ischemic stroke. BRILINTA will be approved for patients who have a contraindication to Effient (e.g., body weight < 60kg, age ≥ 75 years OR who have had a hypersensitivity reaction to clopidogrel or prasugrel AND must be taking a maintenance dose of aspirin not exceeding 100 mg/day. Ticlopidine should only be considered for patients who can be monitored for neutropenia and thrombocytopenia during the first four months of therapy. ZONTIVITY will require manual review.
ATYPICAL ANTI-PSYCHOTICS (oral) <i>Effective 4/1/2014</i>	No PA Required** ABILIFY (aripiprazole) ABILIFY ODT (aripiprazole) clozapine CLOZARIL (clozapine) GEODON (Ziprasidone)	PA Required FANAPT (iloperidone) FAZACLO (clozapine) INVEGA (paliperidone) SAPHRIS (asenapine) SEROQUEL XR (quetiapine)	<i>*IR quetiapine when given at sub therapeutic doses may be restricted for therapy exceeding 30 days. Low-dose quetiapine (<150mg/day) is only FDA approved as part of a drug titration schedule to aid patients in getting to the target quetiapine dose. PA will be required for quetiapine < 150mg per day for longer than 30 days, except for utilization (when appropriate) in members age 65 years or older.</i> Non-preferred products will only be approved for their FDA approved indications and age limits and only if the member has failed on three preferred products in the last 5 years. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). See Table 1.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
	LATUDA (lurasidone) olanzapine risperidone risperidone ODT RISPERDAL (risperidone) RISPERDAL ODT (risperidone) quetiapine* SEROQUEL IR* (quetiapine) ziprasidone ZYPREXA (olanzapine)	ZYPREXA ZYDIS (olanzapine) * for injectable Atypical Antipsychotics please see Appendix P for criteria	<p>**Age Limits: All products including preferred products will require a PA for members younger than the FDA approved age for the agent. Members younger than the FDA approved age for the agent who are currently stabilized on an atypical antipsychotic will be eligible for grandfathering. See Table 3.</p> <p>New Atypical Antipsychotic prescriptions for members under 5 years of age will be reviewed on an individual basis by a clinical health care professional at the Department. PA approval will be based upon medical necessity, evidence to support therapy, proposed monitoring and additional risk/benefit information supplied by the prescriber. Members under 5 years will be reviewed annually for appropriateness of therapy and proper monitoring.</p> <p>Grandfathering: Members currently stabilized on a non-preferred atypical antipsychotic can receive approval to continue on that agent for two years even if the member does not meet the age, dosing or FDA approved indication requirements. Verification may be provided from the prescriber or the pharmacy.</p> <p>Quantity Limits: All products including preferred products will have quantity limits. In order to receive approval for off-label dosing, the member must have an FDA approved indication and must have tried and failed on the FDA approved dosing regimen. See Table 2.</p> <p>Fazaclo will be approved for the treatment of schizophrenia if the member is 18 years of age or older and has tried and failed treatment with three preferred products (one of which must be generic clozapine) in the last 5 years.</p> <p>Invega will be approved for the treatment of schizophrenia or schizoaffective disorder if the member is 18 years of age or older (12 years or older for schizophrenia) and has tried and failed treatment with / has had adherence issues with three preferred products in the last 5 years. A maximum of one tablet per day will be approved.</p> <p>Seroquel XR will be approved if the member is 18 years of age or older, has tried and failed treatment with three preferred products in the last</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			<p>five years and is being treated for one of the FDA approved indications. See Table 1.</p> <p>If a member has been stabilized on quetiapine for at least 30 days with a positive response but is unable to tolerate the side effects, Seroquel XR may be approved without failure of two additional agents.</p> <p>Zyprexa Zydis will be approved for the treatment of schizophrenia or bipolar 1 disorder if the member is 13 years of age or older and has tried and failed treatment with three preferred products (one of which must be an olanzapine tablet) in the last 5 years.</p> <p>For members that are stabilized on Zyprexa tablets with a documented need for occasional supplementation to treat acute symptoms, up to 5 tablets per month will be allowed without three product failures.</p> <p>Table 1: Approved Indications</p> <table border="1" data-bbox="1241 753 2032 1300"> <thead> <tr> <th data-bbox="1241 753 1440 786">Drug</th> <th data-bbox="1440 753 2032 786">Indication</th> </tr> </thead> <tbody> <tr> <td data-bbox="1241 786 1440 818">Fanapt®</td> <td data-bbox="1440 786 2032 818"> <ul style="list-style-type: none"> Acute treatment of schizophrenia in adults </td> </tr> <tr> <td data-bbox="1241 818 1440 948">Fazaclo®</td> <td data-bbox="1440 818 2032 948"> <ul style="list-style-type: none"> Treatment-resistant schizophrenia Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder </td> </tr> <tr> <td data-bbox="1241 948 1440 1013">Invega®</td> <td data-bbox="1440 948 2032 1013"> <ul style="list-style-type: none"> Schizophrenia Schizoaffective disorder </td> </tr> <tr> <td data-bbox="1241 1013 1440 1300">Seroquel XR®</td> <td data-bbox="1440 1013 2032 1300"> <ul style="list-style-type: none"> Treatment of schizophrenia Acute treatment of manic or mixed episodes associated with bipolar I disorder, as monotherapy or as an adjunct to lithium or divalproex Maintenance treatment of bipolar I disorder as an adjunct to lithium or divalproex Adjunctive treatment of major depressive disorder (MDD) </td> </tr> </tbody> </table> <p>Table 2: Quantity Limits</p> <table border="1" data-bbox="1241 1360 2032 1451"> <thead> <tr> <th data-bbox="1241 1360 1388 1451">Brand Name</th> <th data-bbox="1388 1360 1570 1451">Generic Name</th> <th data-bbox="1570 1360 2032 1451">Quantity Limits</th> </tr> </thead> </table>	Drug	Indication	Fanapt®	<ul style="list-style-type: none"> Acute treatment of schizophrenia in adults 	Fazaclo®	<ul style="list-style-type: none"> Treatment-resistant schizophrenia Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder 	Invega®	<ul style="list-style-type: none"> Schizophrenia Schizoaffective disorder 	Seroquel XR®	<ul style="list-style-type: none"> Treatment of schizophrenia Acute treatment of manic or mixed episodes associated with bipolar I disorder, as monotherapy or as an adjunct to lithium or divalproex Maintenance treatment of bipolar I disorder as an adjunct to lithium or divalproex Adjunctive treatment of major depressive disorder (MDD) 	Brand Name	Generic Name	Quantity Limits
Drug	Indication															
Fanapt®	<ul style="list-style-type: none"> Acute treatment of schizophrenia in adults 															
Fazaclo®	<ul style="list-style-type: none"> Treatment-resistant schizophrenia Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder 															
Invega®	<ul style="list-style-type: none"> Schizophrenia Schizoaffective disorder 															
Seroquel XR®	<ul style="list-style-type: none"> Treatment of schizophrenia Acute treatment of manic or mixed episodes associated with bipolar I disorder, as monotherapy or as an adjunct to lithium or divalproex Maintenance treatment of bipolar I disorder as an adjunct to lithium or divalproex Adjunctive treatment of major depressive disorder (MDD) 															
Brand Name	Generic Name	Quantity Limits														

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			Abilify	aripiprazole	Maximum one tablet per day																	
				clozapine	Maximum dosage of 900mg per day																	
			Fazaclo	clozapine	Maximum dosage of 900mg per day																	
			Fanapt	iloperidone	Maximum two tablets per day																	
			Invega	paliperidone	Maximum one tablet per day																	
			Latuda	lurasidone	Maximum one tablet per day																	
				olanzapine	Maximum one tablet per day (see Zyprexa Zydis criteria for Zydis information)																	
				quetiapine	Maximum three tablets per day																	
				risperidone	Maximum two tablets per day except 4mg tablets will be approved for up to 4 tablets per day																	
			Saphris	asenapine	Maximum two tablets per day																	
			Seroquel XR	quetiapine XR	Maximum one tablet per day (for 300mg & 400mg tablets max 2 tablets per day)																	
				ziprasidone	Maximum two tablets per day																	
			Table 3: FDA Approved Dosing by Age																			
			<table border="1"> <thead> <tr> <th data-bbox="1247 982 1451 1084">Drug</th> <th data-bbox="1451 982 1745 1084">FDA Approved Indication</th> <th data-bbox="1745 982 1902 1084">FDA Approved Age</th> <th data-bbox="1902 982 2024 1084">Maximal FDA Approved Dose</th> </tr> </thead> <tbody> <tr> <td data-bbox="1247 1084 1451 1154">Asenapine (Saphris®)</td> <td colspan="3" data-bbox="1451 1084 2024 1154">NOT APPROVED</td> </tr> <tr> <td data-bbox="1247 1154 1451 1284">Aripiprazole (Abilify®)</td> <td data-bbox="1451 1154 1745 1284">Autism/Psychomotor Agitation Bipolar Disorder/Mixed Mania Schizophrenia</td> <td data-bbox="1745 1154 1902 1284">6-17 years 10-17 years 13-17 years</td> <td data-bbox="1902 1154 2024 1284">15mg/day 30mg/day 30mg/day</td> </tr> <tr> <td data-bbox="1247 1284 1451 1354">Clozapine (Fazaclo®, Clozaril®)</td> <td colspan="3" data-bbox="1451 1284 2024 1354" rowspan="2">NOT APPROVED</td> </tr> <tr> <td data-bbox="1247 1354 1451 1425">Iloperidone (Fanapt®)</td> </tr> </tbody> </table>						Drug	FDA Approved Indication	FDA Approved Age	Maximal FDA Approved Dose	Asenapine (Saphris®)	NOT APPROVED			Aripiprazole (Abilify®)	Autism/Psychomotor Agitation Bipolar Disorder/Mixed Mania Schizophrenia	6-17 years 10-17 years 13-17 years	15mg/day 30mg/day 30mg/day	Clozapine (Fazaclo®, Clozaril®)	NOT APPROVED
Drug	FDA Approved Indication	FDA Approved Age	Maximal FDA Approved Dose																			
Asenapine (Saphris®)	NOT APPROVED																					
Aripiprazole (Abilify®)	Autism/Psychomotor Agitation Bipolar Disorder/Mixed Mania Schizophrenia	6-17 years 10-17 years 13-17 years	15mg/day 30mg/day 30mg/day																			
Clozapine (Fazaclo®, Clozaril®)	NOT APPROVED																					
Iloperidone (Fanapt®)																						

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)	
------------------------	------------------	----------------------	---	--

			Lurasidone (Latuda®)			
			Olanzapine (Zyprexa®)	Schizophrenia Bipolar Disorder/Mixed Mania	13-17 years	10mg/day
			Olanzapine (Zyprexa Zydis®)		13-17 years	10mg/day
			Paliperidone (Invega ER®)	Schizophrenia	12-17 years	12mg/day
			Risperidone (Risperdal®)	Autism/Psychomotor Agitation Bipolar Disorder/Mixed Mania Schizophrenia	5-16 years 10-17 years 13-17 years	3mg/day 6mg/day 6mg/day
			Quetiapine Fumarate (Seroquel®)	Schizophrenia Bipolar Disorder/Mixed Mania	13-17 years 10-17 years	800 mg/day 800 mg/day
			Quetiapine Fumarate (Seroquel XR®)	NOT APPROVED		
			Ziprasidone (Geodon®)	NOT APPROVED		
BISPHOSPHONATES (oral) <i>Effective 10/1/2014</i>	No PA Required alendronate (generic) 5mg, 10mg, 35mg, 70mg tablets	PA Required ACTONEL (risedronate) ACTONEL w/Calcium (risedronate w/calcium) BINOSTO (alendronate) BONIVA (ibandronate) DIDRONEL (etidronate) FOSAMAX (alendronate) FOSAMAX plus D (alendronate w/D) Etidronate	Non-preferred products will be approved for members who have failed treatment with at least one strength of alendronate. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.) PA will be approved for etidronate in members with heterotopic ossification without treatment failure. For members who have a low risk of fracture, prior authorization will be required for members exceeding 5 years of either a preferred or non-preferred bisphosphonate. Low risk will be defined as having an osteopenic bone mineral density (most recent T-score between -1 and -2.5) AND has a FRAX score corresponding to low risk.			

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
DIABETES MANAGEMENT CLASSES Amylin <i>Effective 10/1/2014</i>	No PA Required	SKELID (tiludronate) PA Required SYMLIN (pramlintide)	<p>Symlin® will only be approved after a member has failed a three month trial of two of the following: metformin, a sulfonylurea, or any of the preferred products (Tradjenta or Byetta). Failure is defined as: lack of efficacy (e.g., hemoglobin A1C \geq 7%), allergy, intolerable side effects, or a significant drug-drug interaction.</p> <p>For all products, dosing will be limited to FDA approved dosing. PA will be required for doses in excess of FDA approved dosing.</p> <p>PA will be approved for Symlin products for members with Diabetes Mellitus Type 1 without failed treatment. (Failure is defined as: lack of efficacy (e.g., hemoglobin A1C \geq 7%), allergy, intolerable side effects, or significant drug-drug interaction.)</p>
Biguanides <i>Effective 10/1/2014</i>	metformin generic 500mg, 850mg, and 1000mg tablets metformin generic extended-release 500mg tablets (generic Glucophage XR)	FORTAMET (metformin) GLUCOPHAGE (brand) (metformin) GLUCOPHAGE XR (brand) (metformin XR) GLUMETZA (metformin) metformin ER 750mg metformin extended-release 500 and 1000mg (generic Fortamet) RIOMET 500mg/5ml (metformin)	<p>Non-preferred products will be approved for members who have failed treatment with two Preferred Products. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.)</p> <p>Liquid metformin will be approved for members who meet one of the following:</p> <ul style="list-style-type: none"> ➤ under the age of 12 ➤ with a feeding tube who have difficulty swallowing
DPP-4 Inhibitor <i>Effective 10/1/2014</i>	*TRAJENTA (linagliptin)	JANUVIA (sitagliptin) NESINA (alogliptin) ONGLYZA (saxagliptin)	<p>*Approval for preferred products require a three month trial of (or documented contraindication to) metformin therapy prior to initiation of therapy.</p> <p>For all products, dosing will be limited to FDA approved dosing. PA will be required for doses in excess of FDA approved dosing.</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
GLP-1 Agonist <i>Effective 10/1/2014</i>	*BYETTA (exenatide)	BYDUREON (exenatide) TANZEUM (albiglutide) VICTOZA (liraglutide)	<p>Non preferred DPP-4 inhibitors will be approved after a member has failed a three month trial of metformin and Tradjenta®. Failure is defined as lack of efficacy (e.g., hemoglobin A1C \geq 7%), allergy, intolerable side effects, or a significant drug-drug interaction.)</p> <p>*Approval for preferred products require a three month trial of (or documented contraindication to) metformin therapy prior to initiation of therapy.</p> <p>For all products, dosing will be limited to FDA approved dosing. PA will be required for doses in excess of FDA approved dosing.</p> <p>Non preferred GLP-1 agonists will be approved after a member has failed a three month trial of metformin and Byetta®. Failure is defined as lack of efficacy (e.g., hemoglobin A1C \geq 7%), allergy, intolerable side effects, or a significant drug-drug interaction.</p> <p>Grandfathering: Members currently stabilized on Victoza® can receive approval to continue on that agent for one year.</p>
Hypoglycemic Combinations <i>Effective 10/1/2014</i>	No PA Required	PA Required ACTOPLUS MET (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin) AVANDARYL (rosiglitazone/glimepiride) DUETACT (glipizide/metformin) GLUCOVANCE (brand) (glyburide/metformin) glyburide/metformin INVOKAMET (canagliflozin/metformin)	<p>Non-preferred products will be approved for members who have been stable on the two individual ingredients for 3 months and have an adherence issue.</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
		JANUMET (sitagliptin/metformin) JENTADUETO (linagliptin/metformin) JUVISYNC (sitagliptin/simvastatin) KAZANO (alogliptin/metformin) KOMBIGLYZE (saxagliptin/metformin) METAGLIP (glipizide/metformin) OSENI (alogliptin/pioglitazone) PRANDIMET (repaglinide/metformin)	
Meglitinides <i>Effective 10/1/2014</i>	No PA Required	PA Required PRANDIN (repaglinide) STARLIX (nateglinide)	Non-preferred products will be approved for members who have failed treatment with one Sulfonylurea (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.)
SGLT-2 Inhibitor <i>Effective 10/1/2014</i>	No PA Required	FARXIGA (dapagliflozin) INVOKANA (canagliflozin) JARDIANCE (empagliflozin)	<p>The SGLT-2 inhibitors will only be approved after a member has failed a three month trial of two of the following: metformin, a sulfonylurea, or any of the preferred products (Byetta or Tradjenta). Failure is defined as: lack of efficacy (e.g., hemoglobin A1C \geq 7%), allergy, intolerable side effects, or a significant drug-drug interaction.</p> <p>The SGLT-2 inhibitors will not be approved for members requiring dialysis or those who are pregnant, or have type 1 diabetes, end stage renal disease or severe renal impairment (defined as a creatinine clearance < 45ml/min).</p> <p>For all products, dosing will be limited to FDA approved dosing. PA will be required for doses in excess of FDA approved dosing.</p>
Thiazolidinediones <i>Effective 10/1/2014</i>	No PA Required pioglitazone	PA Required ACTOS (pioglitazone)	<p>*Note: Agents in this class may be associated with increased cardiovascular risks. Risk/benefit analysis should be considered before initiating therapy. Prior authorizations for rosiglitazone will be manually</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
ERYTHROPOIESIS STIMULATING AGENTS <i>Effective 10/1/2014</i>	<p>*Must meet eligibility criteria</p> <p>PROCRIPT (epoetin alfa)</p>	<p>AVANDIA (rosiglitazone)</p> <p>PA Required</p> <p>ARANESP (darbepoetin alfa)</p> <p>EPOGEN (epoetin alfa)</p>	<p>reviewed by the Department based upon reported risk mitigation, medical justification and contraindication to pioglitazone.</p> <p>*Eligibility Criteria for all agents in the class Members must meet all criteria in one of the following four areas:</p> <ul style="list-style-type: none"> ➤ A diagnosis of cancer, currently receiving chemotherapy, with chemotherapy-induced anemia, and hemoglobin of 10g/dL or lower. ➤ A diagnosis of chronic renal failure, and hemoglobin below 10g/dL ➤ A diagnosis of hepatitis C, currently taking Ribavirin and failed response to a reduction of Ribavirin dose, and hemoglobin less than 10g/dL (or less than 11g/dL if symptomatic). ➤ A diagnosis of HIV, currently taking Zidovudine, hemoglobin less than 10g/dL, and serum erythropoietin level of 500mUnits/mL or less. <p>Hemoglobin results must be from the last 30 days. Medication must be administered in the member's home or long-term care facility.</p> <p>Non-preferred products:</p> <ul style="list-style-type: none"> ➤ Same as above; and ➤ Failed treatment with Procrit. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.) <p>Note: The FDA has announced a risk evaluation mitigation strategy for the use of Erythropoiesis Stimulating Agents (ESAs) in patients with cancer, who are currently receiving chemotherapy, and who are experiencing chemotherapy induced anemia. Patients must receive a medication guide outlining the risks and benefits of treatment, and patient consent must be obtained before therapy. Prescribers are required to enroll and register in the ESA APPRISE Oncology program and complete training prior to prescribing ESAs to patients with cancer. For non-cancer indications, the distribution of a medication guide to the patient is the only requirement currently.</p>
FIBROMYALGIA AGENTS <i>Effective 7/1/2014</i>	<p>No PA Required</p> <p>LYRICA</p>	<p>PA Required</p> <p>CYMBALTA (duloxetine)</p>	<p>Cymbalta and duloxetine will be approved for fibromyalgia if ALL of the following criteria have been met:</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
	(pregabalin) SAVELLA (milnacipran)	duloxetine	<ul style="list-style-type: none"> • Failure of an adequate trial (8 weeks) of at least two of the following: tramadol, a tricyclic antidepressant, and appropriately titrated dosed gabapentin (1200-2400 mg in divided doses); AND • Documented non-pharmacologic therapies to the Department (e.g, cognitive behavioral therapies, exercise). For members with no epilepsy diagnosis in the last two years (as confirmed by SMART PA), PA will be required for LYRICA prescriptions requiring more than 3 capsules per day or for prescriptions requiring doses greater than 600mg per day.
FLUOROQUINOLONE (oral) <i>Effective 1/1/2014</i>	No PA Required Ciprofloxacin tablet CIPRO oral suspension (<5 years old) Levofloxacin tablet	PA Required AVELOX (moxifloxacin) CIPRO TABLET (ciprofloxacin) LEVAQUIN TABLET (levofloxacin) NOROXIN (norfloxacin) Ofloxacin	Non-preferred products will be approved for members who have failed an adequate trial (7days) with at least one preferred product. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.) CIPRO suspension approved for members < 5 years of age without PA For members ≥ 5 years of age, CIPRO suspension will only be approved for those members who cannot swallow a whole or crushed tablet Levofloxacin solution will be approved for members who have failed an adequate trial (7days) of ciprofloxacin suspension. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.)
GROWTH HORMONES <i>Effective 4/1/2014</i>	No PA Required NORDITROPIN (Somatropin) OMNITROPE (Somatropin) SAIZEN (Somatropin)	PA Required GENOTROPIN HUMATROPE NUTROPIN SEROSTIM TEV-TROPIN ZORBTIVE	Non-preferred Growth Hormones will be approved if both of the following criteria are met: <ul style="list-style-type: none"> ▪ Member failed treatment with two preferred products within the last 12 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) ▪ Member has a qualifying diagnosis: <ul style="list-style-type: none"> ➢ Prader-Willi ➢ Chronic renal insufficiency/failure ➢ Turner’s Syndrome ➢ Hypopituitarism: as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy or trauma ➢ Wasting associated with AIDS or cachexia ➢ Noonan Syndrome

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

HEPATITIS C VIRUS TREATMENTS <i>Effective 10/1/2014</i>	No PA Required	PA Required INCIVEK (Telaprevir) OLYSIO (Simeprevir) SOVALDI (Sofosbuvir) VICTRELIS (boceprevir)	<p>All hepatitis C virus treatments will be approved on a case by case basis.</p> <p>Requests for Victrelis® will be approved if the following criteria are met:</p> <ul style="list-style-type: none"> <input type="checkbox"/> A documented diagnosis of Hepatitis C Genotype 1 with no HIV co-infection AND concurrent therapy with ribavirin and pegylated interferon. <input type="checkbox"/> The patient will be on a treatment regimen of ribavirin and pegylated interferon for four (4) weeks prior to initiation of Victrelis. <input type="checkbox"/> The patient is eighteen (18) years or older. <input type="checkbox"/> The patient is not receiving strong CYP3A4 inducer (e.g., rifampin, rifabutin, phenytoin). <input type="checkbox"/> Member must be 6 months free of: alcohol and Schedule I controlled substances (including marijuana); and cocaine, opiate, benzodiazepine, and barbiturate misuse/abuse as documented by appropriate alcohol/drug screens. Member must also be counseled about the importance of refraining from alcohol use and drug misuse/abuse. Routine alcohol/drug screens must be conducted monthly for clients that have a history (within the past 2 years) of alcohol/drug abuse. <input type="checkbox"/> The patient's previous treatment history and weight are presented at the time of initial request <input type="checkbox"/> The patient's Child-Pugh score is <6 (compensated cirrhotic liver disease). <input type="checkbox"/> The patient has not previously tried/failed therapy with a hepatitis C protease inhibitor (e.g. Incivek® or Olysio®). <input type="checkbox"/> The patient is not a pregnant female or a male with a pregnant female partner (ribavirin contraindication). <input type="checkbox"/> Victrelis® is prescribed by or in conjunction with an infectious disease specialist, gastroenterologist, or hepatologist. <input type="checkbox"/> A sensitive RT-PCR assay HCV-RNA test with a lower limit of quantification of ≤25 IU/ml and a limit of detection of approximately 10 to 15 IU/ml is required to be submitted before the start of therapy. <p>Requests for Incivek® will be approved if the following criteria are met:</p> <ul style="list-style-type: none"> <input type="checkbox"/> A documented diagnosis of Hepatitis C Genotype 1 with no HIV co-infection AND concurrent therapy with ribavirin and pegylated interferon.
---	-----------------------	---	--

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			<ul style="list-style-type: none"> <input type="checkbox"/> The patient is eighteen (18) years or older. <input type="checkbox"/> The patient's previous treatment history and weight are presented at the time of initial request. <input type="checkbox"/> Member must be 6 months free of: alcohol and Schedule I controlled substances (including marijuana); and cocaine, opiate, benzodiazepine, and barbiturate misuse/abuse as documented by appropriate alcohol/drug screens. Member must also be counseled about the importance of refraining from alcohol use and drug misuse/abuse. Routine alcohol/drug screens must be conducted monthly for clients that have a history (within the past 2 years) of alcohol/drug abuse. <input type="checkbox"/> The patient's Child-Pugh score is <6 (compensated cirrhotic liver disease). <input type="checkbox"/> The patient is not receiving strong CYP3A4 inducer (e.g., rifampin, rifabutin, phenytoin) or drug dependent on CYP3A4 clearance (e.g., alfuzosin, cisparide, dihydroergotamine, ergonovine, ergotamine, lovastatin, sildenafil, tadalafil, simvastatin, triazolam). <input type="checkbox"/> The patient has not previously tried/failed therapy with a hepatitis C protease inhibitor (e.g. Victrelis® or Olysio®). <input type="checkbox"/> The patient is not a pregnant female or a male with a pregnant female partner (ribavirin contraindication). <input type="checkbox"/> Incivek® is prescribed in conjunction with an infectious disease specialist, gastroenterologist, or hepatologist. <input type="checkbox"/> A sensitive RT-PCR assay HCV-RNA test with a lower limit of quantification of ≤ 25 IU/ml and a limit of detection of approximately 10 to 15 IU/ml is required to be submitted before the start of therapy. <p>Requests for Olysio® will be approved if the following criteria are met:</p> <ul style="list-style-type: none"> <input type="checkbox"/> A documented diagnosis of Hepatitis C Genotype 1 with no HIV co-infection AND concurrent therapy with ribavirin and pegylated interferon. <input type="checkbox"/> The patient is eighteen (18) years or older. <input type="checkbox"/> The patient's previous treatment history and weight are presented at the time of initial request. <input type="checkbox"/> Member must be 6 months free of: alcohol and Schedule I controlled substances (including marijuana); and cocaine, opiate, benzodiazepine, and barbiturate misuse/abuse as
--	--	--	---

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
			<p>documented by appropriate alcohol/drug screens. Member must also be counseled about the importance of refraining from alcohol use and drug misuse/abuse. Routine alcohol/drug screens must be conducted monthly for clients that have a history (within the past 2 years) of alcohol/drug abuse.</p> <ul style="list-style-type: none"> <input type="checkbox"/> The patient's Child-Pugh score is <6 (compensated cirrhotic liver disease). <input type="checkbox"/> The patient is not receiving moderate to strong inhibitors (e.g, erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, delavirdine, and milk thistle) or inducers (e.g, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, dexamethasone, efavirenz, etravirine, nevirapine, darunavir/ritonavir, ritonavir, and St Johns Wort) of CYP3A4. <input type="checkbox"/> The patient has not previously tried/failed therapy with a hepatitis C protease inhibitor (e.g. Incivek® or Victrelis®). <input type="checkbox"/> The patient is not a pregnant female or a male with a pregnant female partner (ribavirin contraindication). <input type="checkbox"/> Women of childbearing potential and their male partners must use two forms of effective (non-hormonal) contraception during treatment and for at least 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. <input type="checkbox"/> Olysio ® is prescribed in conjunction with an infectious disease specialist, gastroenterologist, or hepatologist. <input type="checkbox"/> A sensitive RT-PCR assay HCV-RNA test with a lower limit of quantification of ≤ 25 IU/ml and a limit of detection of approximately 10 to 15 IU/ml is required to be submitted before the start of therapy. <input type="checkbox"/> For patients with HCV genotype 1a, evidence should be provided that the patient does not have NS3 Q80K polymorphism prior to starting therapy. <p>Requests for Sovaldi® will be prior authorized if the following criteria are met:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Member must have chronic Hepatitis C (HCV) genotype 1, 2, 3 (on transplant list only) or 4 AND <input type="checkbox"/> Member is 18 years of age and older AND

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
			<ul style="list-style-type: none"> <input type="checkbox"/> Women of childbearing potential and their male partners must use two forms of effective (non-hormonal) contraception during treatment. Initial pregnancy test must be performed prior to beginning therapy. <input type="checkbox"/> Sofosbuvir is prescribed by or in conjunction with an infectious disease specialist, gastroenterologist, or hepatologist AND <input type="checkbox"/> Member meets one of the following categories based on liver biopsy, symptoms or other accepted test: <input type="checkbox"/> Member with serious extra-hepatic manifestations of HCV such as leukocytoclastic vasculitis, membranoproliferative glomerulonephritis, or symptomatic cryoglobulinemia despite mild liver disease; <input type="checkbox"/> Member with cirrhosis with evidence of hepatic dysfunction as defined by one of the following: Child-Turcotte Pugh (CTP) class A or B (Score 5-9) ascites, hepatic encephalopathy, or variceal bleeding, and on the liver transplant list with a projected time to transplant of < 1 year; <input type="checkbox"/> Member is listed on the liver transplant list with a projected time to transplant of < 1 year (genotype: 1 naïve, 1 experienced, 2, 3, and 4); <input type="checkbox"/> Member has hepatocellular carcinoma meeting Milan criteria; or <input type="checkbox"/> Member has a fibrosis score equivalent to METAVIR 3-4. <input type="checkbox"/> For members with Genotype 1, must be Hepatitis C treatment naïve AND <input type="checkbox"/> Member does not have severe renal impairment (eGFR<30 ml/min/1.73m²) or end stage renal disease requiring hemodialysis AND <input type="checkbox"/> Member must be 6 months free of: alcohol and Schedule I controlled substances (including marijuana); and cocaine, opiate, benzodiazepine, and barbiturate misuse/abuse as documented by appropriate alcohol/drug screens. Member must also be counseled about the importance of refraining from alcohol use and drug misuse/abuse. Routine alcohol/drug screens must be conducted monthly for clients that have a history (within the past 2 years) of alcohol/drug abuse AND <input type="checkbox"/> Member must have a baseline HCV RNA level within 30 days of anticipated start date AND

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			<ul style="list-style-type: none"> <input type="checkbox"/> Member is not receiving concomitant treatment with a hepatitis protease inhibitor (e.g. simeprevir, telaprevir or boceprevir) AND <input type="checkbox"/> All approvals will initially be for a 8 week time period, with further approvals dependent on the submission of the HCV RNA level at 4, at week 12, and week 24 to justify continuing drug therapy (see discontinuation criteria) AND <input type="checkbox"/> If the week 4 HCV RNA is detectable while on sofosbuvir therapy, HCV RNA will be reassessed in 2 weeks. If the repeated HCV RNA level has not decreased (i.e. >1 log₁₀ IU/ml from nadir) all treatment will be discontinued unless documentation is provided to support continuation of therapy AND <input type="checkbox"/> Must be in accordance to approved regimens and duration (see Table 1) AND <input type="checkbox"/> Must be adherent to treatment regimen (see discontinuation criteria) AND <input type="checkbox"/> Must be Sofosbuvir naïve <p><u>Note:</u> Once treated, the Department will only cover a once per lifetime treatment with Sofosbuvir.</p> <p>Discontinuation Criteria:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Members receiving a Sofosbuvir based regimen should have HCV RNA levels assessed at weeks, 4, 6 (if applicable), and 12 (if applicable); if the HCV RNA is above the lower limit of quantification by a validated test at any of these time points, all treatment will be discontinued. <input type="checkbox"/> The department will prospectively evaluate medication adherence based on prescription fills. If a member is non-adherent in filling their Sofosbuvir prescription (e.g. not filled within 7 days of the end of the previous fill), all treatment will be discontinued. <p>Table 1. Recommended Regimens and Treatment Duration for Sofosbuvir</p> <table border="1" data-bbox="1285 1377 2001 1425"> <thead> <tr> <th data-bbox="1285 1377 1600 1425">HCV Genotype</th> <th data-bbox="1600 1377 1850 1425">Treatment</th> <th data-bbox="1850 1377 2001 1425">Duration</th> </tr> </thead> </table>	HCV Genotype	Treatment	Duration
HCV Genotype	Treatment	Duration				

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			<table border="1" data-bbox="1285 235 2001 841"> <tbody> <tr> <td data-bbox="1293 235 1598 331">Genotype 1: interferon eligible</td> <td data-bbox="1598 235 1852 331">Sofosbuvir + peginterferon alfa + ribavirin</td> <td data-bbox="1852 235 1992 331">12 weeks</td> </tr> <tr> <td data-bbox="1293 331 1598 396">Genotype 1: interferon ineligible</td> <td data-bbox="1598 331 1852 396">Sofosbuvir + ribavirin</td> <td data-bbox="1852 331 1992 396">24 weeks</td> </tr> <tr> <td data-bbox="1293 396 1598 461">Genotype 2:</td> <td data-bbox="1598 396 1852 461">Sofosbuvir + ribavirin</td> <td data-bbox="1852 396 1992 461">12 weeks</td> </tr> <tr> <td data-bbox="1293 461 1598 526">Genotype 3: on transplant list</td> <td data-bbox="1598 461 1852 526">Sofosbuvir + ribavirin</td> <td data-bbox="1852 461 1992 526">24 weeks</td> </tr> <tr> <td data-bbox="1293 526 1598 621">Genotype 4: interferon eligible</td> <td data-bbox="1598 526 1852 621">Sofosbuvir + peginterferon alfa + ribavirin</td> <td data-bbox="1852 526 1992 621">12 weeks</td> </tr> <tr> <td data-bbox="1293 621 1598 717">Genotype 4: interferon ineligible</td> <td data-bbox="1598 621 1852 717">Sofosbuvir + ribavirin</td> <td data-bbox="1852 621 1992 717">24 weeks</td> </tr> <tr> <td colspan="3" data-bbox="1293 717 1992 841">Post-transplant members follow the same treatment regimen as described above.</td> </tr> </tbody> </table> <p data-bbox="1241 873 1535 899"><u>Quantity and Refill Limits:</u></p> <p data-bbox="1241 906 1898 932">Quantity Limit: one 400mg tablet per day (28 tablets/28days)</p> <p data-bbox="1241 938 1759 964">Length of authorization: Based on HCV subtype</p> <p data-bbox="1241 971 1997 1052">Refills: Should be reauthorized in order to continue the appropriate treatment plan. The member MUST receive refills within one week of completing the previous fill.</p> <p data-bbox="1241 1089 1650 1115">Interferon Alpha Ineligible defined:</p> <ul data-bbox="1293 1122 2018 1367" style="list-style-type: none"> <input type="checkbox"/> Platelet count <75,000mm³ <input type="checkbox"/> Decompensated liver cirrhosis (CTP Class B or C or CTP score ≥ 7) <input type="checkbox"/> Documented history of depression or mood disorder, which are not stable on current drug regimen <input type="checkbox"/> Autoimmune hepatitis and another autoimmune disorder <input type="checkbox"/> Inability to complete a prior treatment course due to a documented interferon-related adverse event. 	Genotype 1: interferon eligible	Sofosbuvir + peginterferon alfa + ribavirin	12 weeks	Genotype 1: interferon ineligible	Sofosbuvir + ribavirin	24 weeks	Genotype 2:	Sofosbuvir + ribavirin	12 weeks	Genotype 3: on transplant list	Sofosbuvir + ribavirin	24 weeks	Genotype 4: interferon eligible	Sofosbuvir + peginterferon alfa + ribavirin	12 weeks	Genotype 4: interferon ineligible	Sofosbuvir + ribavirin	24 weeks	Post-transplant members follow the same treatment regimen as described above.		
Genotype 1: interferon eligible	Sofosbuvir + peginterferon alfa + ribavirin	12 weeks																						
Genotype 1: interferon ineligible	Sofosbuvir + ribavirin	24 weeks																						
Genotype 2:	Sofosbuvir + ribavirin	12 weeks																						
Genotype 3: on transplant list	Sofosbuvir + ribavirin	24 weeks																						
Genotype 4: interferon eligible	Sofosbuvir + peginterferon alfa + ribavirin	12 weeks																						
Genotype 4: interferon ineligible	Sofosbuvir + ribavirin	24 weeks																						
Post-transplant members follow the same treatment regimen as described above.																								

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
Insulin <i>Effective 4/1/2014</i> Rapid Acting	No PA Required HUMALOG vial and pen NOVOLOG vial and pen	PA Required APIDRA all forms	Non-preferred products will be approved if the member has failed treatment with one of the preferred products in the last month (Failure is defined as: allergy or intolerable side effects)
Short Acting	HUMULIN R vial and pen	NOVOLIN R all forms	Non-preferred products will be approved if the member has failed treatment with one of the preferred products in the last month (Failure is defined as: allergy or intolerable side effects)
Intermediate Acting	HUMULIN N vial and pen	NOVOLIN N all forms	Non-preferred products will be approved if the member has failed treatment with one of the preferred products in the last month (Failure is defined as: allergy or intolerable side effects)
Long Acting	LEVEMIR vial and pen	LANTUS all forms	Non-preferred products will be approved if the member has failed treatment with one of the preferred products in the last month (Failure is defined as: allergy or intolerable side effects)
Mixtures	HUMULIN 70/30 vial and pen NOVOLIN 70/30 vial HUMALOG MIX 50/50 vial and pen HUMALOG MIX 75/25 vial and pen NOVOLOG MIX 70/30 vial and pen	None	Non-preferred products will be approved if the member has failed treatment with one of the preferred products in the last month (Failure is defined as: allergy or intolerable side effects)
INTRANASAL CORTICOSTEROIDS <i>Effective 4/1/2014</i>	No Prior Authorization Required fluticasone (generic FLONASE) NASONEX	Prior Authorization Required BECONASE AQ (beclomethasone dipropionate) FLONASE (fluticasone) NASAREL (flunisolide) NASACORT AQ (triamcinolone) OMNARIS (ciclesonide)	Non-preferred Intranasal Corticosteroids will be approved if the client has failed treatment with 2 preferred products in the last 12 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). ★ Rhinocort AQ will be approved for pregnant clients without failure of Preferred products. ★ Brand name Flonase will require a letter of medical necessity

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
		QNASL (beclomethasone dipropionate) RHINOCORT AQ (budesonide) Triamcinolone acetonide VERAMYST (fluticasone furoate) ZETONNA (ciclesonide)	
LEUKOTRIENE MODIFIERS <i>Effective 4/1/2014</i>	No Prior Authorization Required Montelukast (generic SINGULAIR)	Prior Authorization Required ACCOLATE (zafirlukast) SINGULAIR (montelukast) ZYFLO (zileuton)	Non-preferred Leukotrienes will be approved if both of the following criteria are met: <ul style="list-style-type: none"> ▪ Client failed treatment with montelukast in the last 12 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) ▪ Client has a diagnosis of Asthma
MULTIPLE SCLEROSIS AGENTS <i>Effective 4/1/2014</i>	No Prior Authorization Required AVONEX (interferon beta 1a) BETASERON (interferon beta 1b) REBIF (interferon beta 1a) COPAXONE 20MG INJECTION (glatiramer)	Prior Authorization Required AMPYRA (dalfampridine) EXTAVIA (interferon beta 1b) GILENYA (fingolimid) AUBAGIO (teriflunomide) TECFIDERA (dimethyl fumarate) COPAXONE 40MG INJECTION (glatiramer)	Non-preferred Interferon products will be approved if the client has failed treatment with three preferred products in the last 12 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). Copaxone® 40mg will be approved for members who have a severe intolerable injection site rejections (e.g, pain requiring local anesthetic, oozing, lipoatrophy, swelling, or ulceration) to Copaxone 20mg. Ampyra – Up to a 90 day supply of Ampyra will be approved if all of the following criteria are met: <ul style="list-style-type: none"> • Client has a diagnosis of MS; • Client is ambulatory and has established a baseline which is defined as ambulating between 8-45 seconds Timed 25-foot Walk (T25FW) assessment; • Client is currently receiving a disease modifying agent (if indicated); • Client has no history of seizure disorder; • Client has no history of moderate to severe renal dysfunction (CrCl > 50 ml/min);

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
			<ul style="list-style-type: none"> • Prescriber is a neurologist; • The prescribed dose does not exceed 10 mg twice daily. <p>Extended coverage of Ampyra (up to one year) will be approved if documentation shows a 20% improvement in ambulation (measured by T25FW assessment) after three months of therapy.</p> <p>AUBAGIO will be approved if the client has met all the following criteria:</p> <ul style="list-style-type: none"> • Has failed six month trial with COPAXONE 20mg or a preferred interferon products. Failure will be defined as intolerable side effects, drug-drug interaction, or lack of efficacy. Lack of efficacy will be defined as one of the following: • One of the following on MRI: presence of new spinal lesions, cerebellar or brain stem lesions, or T2 or T1 lesions, or change in brain atrophy. • On clinical exam, signs and symptoms consistent with functional limitations, except sensory relapse, that last one month or longer. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> • Has a diagnosis of a relapsing form of MS AND • Is being prescribed by a neurologist AND • Has no active infections AND • If a female patient of child bearing age, has a negative pregnancy test at baseline and is using a form of highly effective contraceptive AND • Had transaminase and bilirubin levels with ALT<2 times the upper limit of normal within the 6 months prior to initiating therapy AND • Had a complete blood count with differential within the six months prior to initiating therapy AND • Has a documented baseline blood pressure AND • Has been evaluated for active or latent tuberculosis infections by documented test results (purified protein derivative test) or blood test.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			<p>TECFIDERA will be approved if the client has met all the following criteria:</p> <ul style="list-style-type: none"> • Has failed six month trial with COPAXONE 20mg or a preferred interferon products. Failure will be defined as intolerable side effects, drug-drug interaction, or lack of efficacy. Lack of efficacy will be defined as one of the following: <ul style="list-style-type: none"> • One of the following on MRI: presence of new spinal lesions, cerebellar or brain stem lesions, or T2 or T1 lesions, or change in brain atrophy. • On clinical exam, signs and symptoms consistent with functional limitations, except sensory relapse, that last one month or longer. <p>AND</p> <ul style="list-style-type: none"> • Has a diagnosis of a relapsing form of MS AND • Is being prescribed by a neurologist AND • Has no active infections AND • Had a complete blood count with differential within the six months prior to initiating therapy. <p>GILENYA will be approved if the client has met all the following criteria:</p> <ul style="list-style-type: none"> • Has failed six month trial with COPAXONE 20mg or a preferred interferon products. Failure will be defined as intolerable side effects, drug-drug interaction, or lack of efficacy. Lack of efficacy will be defined as one of the following: <ul style="list-style-type: none"> • One of the following on MRI: presence of new spinal lesions, cerebellar or brain stem lesions, or T2 or T1 lesions, or change in brain atrophy. • On clinical exam, signs and symptoms consistent with functional limitations, except sensory relapse, that last one month or longer. <p>AND</p> <ul style="list-style-type: none"> • Has a diagnosis of a relapsing form of MS AND • Is being prescribed by a neurologist AND
--	--	--	--

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
			<ul style="list-style-type: none"> • Does not have a recent history of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or New York Heart Association Class III-IV heart failure within six months of initiating therapy <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> • Does not have a history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome unless patient has a pacemaker <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> • Has a baseline QTc interval <500 ms prior to starting therapy AND • Is not receiving treatment with a Class Ia or Class III anti-arrhythmic medication AND • Has no active infections AND • Had an ophthalmologic evaluation (ocular coherence test) prior to starting therapy within 3-4 months after starting therapy AND • Had a baseline complete blood count with differential and liver function tests.
OPHTHALMIC ALLERGY <i>Effective 4/1/2014</i>	No Prior Authorization Required Cromolyn (generic for Nasalcrom) PATANOL (olopatadine) PATADAY (olopatadine)	Prior Authorization Required ALAMAST (pemirolast) ALAWAY (ketotifen) ALOCRIL (nedocromil) ALOMIDE (lodoxamide) BEPREVE (bepotastine) ELESTAT (epinastine) EMADINE (emedastine) LASACRAFT (alcaftadine)	Non-preferred Ophthalmic Allergy medications will be approved if the client has failed treatment with two preferred products in the last 12 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions)

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
		OPTICROM (sodium cromoglicate) OPTIVAR (azelastine) ZADITOR (ketotifen)	
OPIOIDS Long Acting – Oral Opioids <i>Effective 7/1/2014</i>	FIRST LINE (No PA Required) fentanyl patches methadone (generic Dolophine) morphine ER (generic MS Contin)	PA Required AVINZA (morphine ER) BUTRANS (buprenorphine) DOLOPHINE (methadone) DURAGESIC (fentanyl patch) EMBEDA (morphine/naltrexone.) KADIAN (morphine ER) MS CONTIN (morphine ER) NUCYNTA ER (tapentadol ER) OPANA ER (oxymorphone ER) ORAMORPH SR (morphine ER) OXYCONTIN (oxycodone ER) TARGINIQ ER (oxycodone ER) XARTEMIS XR (oxycodone/acetaminophen) ZOHYDRO ER (hydrocodone ER)	<p>Non-preferred, long-acting oral opioids will be approved for members who have failed treatment with two preferred agents in the last six months. (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.)</p> <p>Fentanyl patches (Duragesic) will require a PA for doses of more than 1 patch/2 days.</p> <p>Butrans patches will be approved for members who have failed treatment with ONE preferred agent in the last 6 months. (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.)</p> <p>Zohydro ER will be approved for members who have failed treatment with two preferred products, AND at least one other long acting opiate in the past year.</p> <p>Oxycontin®, Opana ER®, Nucynta ER®, and Zohydro ER® will only be approved for twice daily dosing.</p> <p>No more than one long-acting oral opioid will be approved at one time.</p> <p>Medicaid is not mandating that a patient switch from a non-preferred drug to methadone. Methadone requires special training due to its complex pharmacokinetic profile. However, if a patient has tried and failed methadone in the past, it can be considered a trial of one preferred drug.</p> <p>Use of opioid analgesics during pregnancy has been associated with neonatal abstinence syndrome. Providers MUST counsel women of childbearing age regarding the risks of becoming pregnant while receiving opioids, including the risk of neonatal abstinence syndrome. Providers should offer access to contraceptive services when necessary.</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
OVERACTIVE BLADDER AGENTS <i>Effective 10/1/14</i>	No Prior Authorization Required oxybutynin tablets (generic) oxybutynin ER tablets (generic) TOVIAZ (fesoterodine ER)	Prior Authorization Required DETROL (tolterodine) DETROL LA (tolterodine ER) DITROPAN (brand) DITROPAN XL (brand) ENABLEX (darifenacin) Flavoxate GELNIQUE (oxybutynin gel) OXYTROL (oxybutynin patch) SANCTURA (trospium) SANCTURA XL (trospium ER) Tolterodine VESICARE (solifenacin) Myrbetriq (mirabegron)	Non-preferred products will be approved for clients who have failed treatment with two preferred products. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.). Clients with hepatic failure can receive approval to receive trospium or trospium extended-release (Sanctura XR) products without a trial on a Preferred product.
PANCREATIC ENZYMES <i>Effective 1/1/2014</i>	No PA Required CREON (pancrelipase) ZENPEP (pancrelipase)	PA Required PANCREAZE (pancrelipase) PANCRELIPASE (pancrelipase) PERTZYE (pancrelipase) ULTRESA (pancrelipase) VIOKACE (pancreatin)	Non-preferred products will be approved for members who have failed an adequate trial (4 weeks) with at least two preferred products. (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.) Grandfathering: Members currently stabilized on a Non-preferred pancreatic enzyme can receive approval to continue on that agent for one year if medically necessary.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
PROTON PUMP INHIBITORS <i>Effective 1/1/2014</i>	<p>*Must meet eligibility criteria</p> <p>ACIPHEX (rabeprazole)</p> <p>lansoprazole 15mg OTC (currently available as PREVACID 24HR)</p> <p>NEXIUM (esomeprazole) capsules and packets</p> <p>omeprazole generic capsules</p> <p>PREVACID solutab ^{BNR} (lansoprazole) (for members under 2)</p>	<p>PA Required</p> <p>ACIPHEX sprinkles (rabeprazole)</p> <p>DEXILANT (dexlansoprazole)</p> <p>KAPIDEX (dexlansoprazole)</p> <p>lansoprazole capsules</p> <p>lansoprazole solutabs</p> <p>pantoprazole</p> <p>PREVACID (lansoprazole) capsules & suspension</p> <p>PRILOSEC OTC (omeprazole)</p> <p>PROTONIX (pantoprazole)</p> <p>ZEGERID (omeprazole/Na bicarbonate)</p>	<p>*PA will be required for therapy beyond 60 days of treatment per year for all agents. For members treated for GERD, once 60 days of therapy per year has been exceeded, members must fail an adequate trial of a histamine 2 receptor antagonist before PPI therapy can be reconsidered. An adequate trial is defined as 8 weeks of histamine 2 receptor antagonist.</p> <p>Long-term therapy will be approved for members with Barrett’s Esophagus, Erosive Esophagitis, GI Bleed, Hypersecretory Conditions (Zollinger Ellison), Recurrent Aspiration Syndrome, chronic NSAID therapy, Spinal Cord Injury members with an acid reflux diagnosis, or children (< 18 years of age) with Cystic Fibrosis, on mechanical ventilation or who have a feeding tube. In addition, members with continuing, symptomatic GERD or recurrent peptic ulcer disease who have documented failure on step-down therapy to an H2-receptor antagonist will be approved for up to one year of daily PPI therapy.</p> <p>Non-preferred proton pump inhibitors will be approved if all of the following criteria are met:</p> <ul style="list-style-type: none"> ➤ Member failed treatment with two Preferred Products within the last 24 months, ➤ Member has a qualifying diagnosis, and ➤ Member has been diagnosed by an appropriate diagnostic method. <p>The Qualifying Diagnoses are: Barrett’s Esophagus, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, GERD, GI Bleed, H. pylori, Hypersecretory Conditions (Zollinger-Ellison), NSAID-Induced Ulcer, Pediatric Esophagitis, Recurrent Aspiration Syndrome or Ulcerative GERD</p> <p>The Appropriate Diagnostic Methods are: GI Specialist, Endoscopy, X-Ray, Biopsy, Blood test, or Breath test</p> <p>Quantity Limits: Non-preferred agents will be limited to once daily dosing except for the following diagnoses: Barrett’s Esophagus, GI Bleed, H. pylori, Hypersecretory Conditions, or Spinal Cord Injury patients with any acid reflux diagnosis.</p> <p>Age Limits:</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
			Aciphex, Protonix, and Zegerid will not be approved for members less than 18 years of age. Prevacid Solutab will be approved for members less than 2 years old and ≥ 2 years with a feeding tube.
H. Pylori Treatments	NONE	HELIDAC (tetracycline/tripotassium dicitrateobismuthate/metronidazole) OMECLAMOX-PAK (amoxicillin/omeprazole/clarithromycin) PREVPAC (amoxicillin/lansoprazole/clarithromycin) PYLERA (bismuth subcitrate/metronidazole/tetracycline)	H. Pylori treatments should be used as individual products unless one of the individual products is not commercially available then a PA for the combination product will be given.
PULMONARY ARTERIAL HYPERTENSION THERAPIES Phosphodiesterase Inhibitors <i>Effective 1/1/2014</i>	*Must meet eligibility criteria ADCIRCA (tadalafil) Sildenafil (generic Revatio)	PA Required REVATIO (sildenafil)	*Eligibility Criteria for all agents in the class Approval will be granted for a diagnosis of pulmonary hypertension.
Endothelin Antagonists <i>Effective 1/1/2014</i>	No PA Required LETAIRIS (ambrisentan)	PA Required OPSUMIT (macitentan) TRACLEER (bosentan)	Non-preferred products will be approved for members who have failed treatment with Letairis or for members requiring a dose preparation not available with a preferred product. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) Grandfathering: Members who have been previously stabilized on a Non-preferred product can receive approval to continue on the medication for one year if medically necessary.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
Prostanoids <i>Effective 1/1/2014</i>	No PA Required epoprostenol (generic) VELETRI (epoprostenol)	PA Required FLOLAN (brand) (epoprostenol) ORENITRAM (treprostiniil) REMODULIN (treprostiniil) TYVASO (treprostiniil) VENTAVIS (iloprost)	Non-preferred products will be approved for members who have failed treatment with a Preferred Product. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, contraindication to IV therapy or significant drug-drug interaction) Grandfathering: Members who have been previously stabilized on a Non-preferred product can receive approval to continue on the medication for one year if medically necessary.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
Guanylate Cyclase (sGC) Stimulator <i>Effective 1/1/2014</i>	No PA Required	PA Required ADEMPAS (riociguat)	Adempas will be approved for patients who meet the following criteria: <ul style="list-style-type: none"> ○ Patient is not a pregnant female and is able to receive monthly pregnancy tests while taking Adempas and one month after stopping therapy. AND ○ Women of childbearing potential and their male partners must use one of the following contraceptive methods during treatment and one month after stopping treatment (e.g, IUD, contraceptive implants, tubal sterilization, a hormone method with a barrier method, two barrier methods, vasectomy with a hormone method, or vasectomy with a barrier method). AND ○ Patient is not receiving dialysis or has severe renal failure (e.g, Crcl < 15 ml/min). AND ○ Patient does not have severe liver impairment (e.g, Child Pugh C). AND ○ Prescriber must be enrolled with the Adempas REMS Program. AND ○ Female patients, regardless of reproductive potential, must be enrolled in the Adempas REMS program prior to starting therapy. AND ○ Patient has a diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or has inoperable CTEPH OR ○ Patient has a diagnosis of pulmonary hypertension and has failed treatment with a preferred product for pulmonary hypertension. (Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions).
RESPIRATORY INHALANTS Inhaled Anticholinergics & Anticholinergic Combinations <i>Effective 7/1/2014</i>	No PA Required <u>Solutions</u> albuterol/ipratropium (generic Duoneb) ipratropium (generic Atrovent) <u>Short-Acting Inhalers</u> ATROVENT HFA (ipratropium)	PA Required <u>Solutions</u> ATROVENT (ipratropium) solution DUONEB (albuterol/ipratropium) <u>Short-Acting Inhalers</u> <u>Long-Acting Inhalers</u> TUDORZA Pressair (aclidinium)	Non-preferred anticholinergic inhalants and anticholinergic combination inhalants will require a brand-name PA stating medical necessity. Tudorza Pressair will be approved for members who have failed treatment with Spiriva Handihaler (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction), or who have a contraindication to Spiriva Handihaler.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	---

	COMBIVENT RESPIMAT (albuterol/ipratropium) <u>Long-Acting Inhalers</u> SPIRIVA Handihaler (tiotropium)	INCRUSE ELLIPTA (umeclidinium) ANORO ELLIPTA (umeclidinium/vilanterol)	
RESPIRATORY INHALANTS Inhaled Beta2 Agonists (short acting) <i>Effective 7/1/2014</i>	<p align="center">No PA Required</p> <p><u>Solutions</u> albuterol (generic) solution</p> <p><u>Inhalers</u> PROAIR (albuterol) HFA inhaler</p>	<p align="center">PA Required</p> <p><u>Solutions</u> ACCUNEB (albuterol) solution AIRET (albuterol) solution ALUPENT (metaproterenol) PROVENTIL (albuterol) soln. VENTOLIN (albuterol) solution XOPENEX (levalbuterol) soln.</p> <p><u>Inhalers</u> ALUPENT (metaproterenol) Inhaler MAXAIR (pirbuterol) autohaler PROVENTIL (albuterol) HFA inhaler VENTOLIN (albuterol) HFA inhaler XOPENEX (levalbuterol) Inhaler</p>	Non-preferred, short acting beta2 agonists will be approved for members who have failed treatment with one preferred agent. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction).

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
RESPIRATORY INHALANTS Inhaled Beta2 Agonists (long acting) <i>Effective 7/1/2014</i>	No PA Required	PA Required <u>Solutions</u> BROVANA (Arformoterol) soln. solution PERFOROMIST (formoterol) solution <u>Inhalers</u> ARCAPTA (indacaterol) neohaler FORADIL (formoterol) inhaler SEREVENT (salmeterol) inhaler STRIVERDI RESPIMAT (olodaterol)	Long acting beta-2 agonists will be approved for members with moderate to severe asthma who are currently using an inhaled corticosteroid and require add-on therapy, or for members with moderate to very severe COPD.
RESPIRATORY INHALANTS Inhaled Corticosteroids <i>Effective 7/1/2014</i>	No PA Required <u>Solutions</u> budesonide nebules <u>Inhalers</u> ASMANEX twist (mometasone) FLOVENT (fluticasone) diskus FLOVENT (fluticasone) HFA QVAR (beclomethasone)	PA Required <u>Inhalers</u> AEROBID (flunisolide) inhaler ALVESCO (ciclesonide) ARNUITY ELLIPTA (fluticasone furoate) AZMACORT (triamcinolone) inhaler PULMICORT (budesonide) flexhaler	Non-preferred inhaled corticosteroids will be approved in members with asthma who have failed an adequate trial of two preferred agents. An adequate trial is defined as at least 6 weeks. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions.) Pulmicort Flexhaler will only be approved without failure on preferred products for female members with asthma who have a new diagnosis of pregnancy. Budesonide nebulizer solution will only be approved for a maximal dose of 2mg/day.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
RESPIRATORY INHALANTS Inhaled Corticosteroid Combinations <i>Effective 7/1/2014</i>	No PA Required ADAIR Diskus (fluticasone/salmeterol) ADAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol)	PA Required BREO Ellipta (vilanterol/fluticasone furoate) SYMBICORT (budesonide/formoterol)	Non-preferred inhaled corticosteroid combination inhalants will be approved for members meeting the following criteria: <ul style="list-style-type: none"> ➤ Member has a qualifying diagnosis of asthma or COPD; and ➤ Members with a diagnosis of asthma will have to fail two preferred agents due to lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction. ➤ Members with a diagnosis of COPD will only have to fail one preferred agent due to lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.
SEDATIVE- HYPNOTICS (non-benzodiazepine) <i>Effective 4/1/2014</i>	No PA Required* (unless duplication criteria apply) LUNESTA (eszopiclone) zaleplon zolpidem	PA Required AMBIEN (zolpidem) AMBIEN CR (zolpidem) EDLUAR (zolpidem) INTERMEZZO (zolpidem) ROZEREM (ramelteon) SONATA (zaleplon) ZOLPIMIST (zolpidem)	Non-preferred sedative hypnotics will be approved for members who have failed treatment with two preferred agents in the last 12 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) Sedative hypnotics will require PA for member's ≥ 65 years of age exceeding 90 days of therapy. Rozerem will be approved for members with a history/concern of substance abuse or for documented concern of diversion within the household without failed treatment on a preferred agent Children: PAs will be approved for members 18 years of age and older. *Duplications: Only one agent in this drug class will be approved at a time. Approval will not be granted for members currently taking a long-acting benzodiazepine such as clonazepam or temazepam.
SKELETAL MUSCLE RELAXANTS <i>Effective 7/1/2014</i>	No PA Required For Members under 75 years of age* baclofen (generic Lioresal) cyclobenzaprine (generic Flexeril)	PA Required AMRIX ER (cyclobenzaprine ER) carisoprodol chlorzoxazone DANTRIUM (dantrolene) dantrolene	All agents in this class will require a PA for members over 65 years of age. Approval will only be given if the member has had at least a 7 day trial with an opiate or has a diagnosis of spasticity. The maximum allowable approval will be for a 7 days' supply. Non-preferred skeletal muscle relaxants will be approved for members who have documented lack of efficacy with two preferred agents in the last 6 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions.)

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
	tizanidine (generic Zanaflex)	FEXMID (cyclobenzaprine) FLEXERIL (cyclobenzaprine) metaxolone methocarbamol NORFLEX (orphenadrine) orphenadrine PARAFLEX (chlorzoxazone) PARAFON FORTE (chlorzoxazone) REMULAR (chlozoxone) ROBAXIN (methocarbamol) SKELAXIN (metaxalone) SOMA (carisoprodal) ZANAFLEX (tizanidine) VANADOM (carisoprodal)	Authorization for any carisoprodol product will be given for a maximum 3 week one time authorization for members with acute, painful musculoskeletal conditions who have failed treatment with two preferred products. Tapering: Due to potential withdrawal symptoms, tapering is recommended when discontinuing high doses of carisoprodol. A one month approval will be granted for members tapering off of carisoprodol. *A PA will only be granted for any carisoprodol product for short-term use or tapering.

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
STATINS <i>Effective 4/1/2014</i>	No PA Required atorvastatin CRESTOR (rosuvastatin) pravastatin simvastatin*	PA Required ALTOPREV (lovastatin ER) LESCOL (fluvastatin) LESCOL XL (fluvastatin ER) LIPITOR (atorvastatin) LIVALO (pitavastatin) lovastatin (generic Mevacor) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR* (simvastatin)	Non-preferred Statin/Statin combinations will be approved if the member has failed treatment with two preferred products in the last 24 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) Children: Altoprev, Advicor, Livalo and Vytorin will be approved for members 18 years of age and older. Caduet, fluvastatin and lovastatin will be approved for members 10 years of age and older. *Simvastatin 80mg dose products will only be covered for members who have been stable for more than 12 months at that dose. Providers should consider alternate preferred statins in members who have not met cholesterol goals on simvastatin at doses up to 40mg per day. Please refer to the FDA communication titled, "FDA Drug Safety Communication: New restrictions, contraindications and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury" for updated guidance on contraindications, dose limits and relative LDL lowering doses of alternatives.
STATIN COMBINATIONS <i>Effective 4/1/2014</i>		ADVICOR (niacin ER / lovastatin) CADUET (amlodipine /atorvastatin) LIPTRUZET (ezetimibe/ atorvastatin) SIMCOR (niacin/simvastatin) VYTORIN* (ezetimibe/simvastatin.)	

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
STIMULANTS and other ADHD agents <i>Effective 10/1/2014</i>	<p>No PA Required (as long as age, daily dose and diagnosis limitations are met)</p> <p>ADDERALL ^{*BNR*} (mixed-amphetamine salts)</p> <p>ADDERALL XR (mixed amphetamine salts ER) ^{*BNR*}</p> <p>FOCALIN (brand name dexmethylphenidate)</p> <p>FOCALIN XR (dexmethylphenidate ER) ^{*BNR*}</p> <p>INTUNIV (guanfacine ER)</p> <p>methylphenidate ER (generic Concerta)</p> <p>RITALIN ^{*BNR*} (methylphenidate)</p> <p>RITALIN SR or LA ^{*BNR*} (methylphenidate SR or LA)</p> <p>STRATTERA (atomoxetine) ^{*BNR*}</p> <p>VYVANSE (lisdexamfetamine)</p>	<p>PA Required</p> <p>CONCERTA (methylphenidate ER)</p> <p>DAYTRANA (methylphenidate transdermal)</p> <p>DESOXYN (methamphetamine)</p> <p>DEXEDRINE (dextroamphetamine)</p> <p>DEXTROSTAT (dextroamphetamine)</p> <p>dexmethylphenidate (generic Focalin XR)</p> <p>KAPVAY (clonidine ER)</p> <p>METADATE CD (methylphenidate ER)</p> <p>METADATE ER (methylphenidate ER)</p> <p>METHYLIN SUSPENSION (methylphenidate)</p> <p>Methylphenidate (generic RITALIN)</p> <p>mixed amphetamine salts (generic for Adderall)</p> <p>mixed-amphetamine salts ER (generic for Adderall XR)</p> <p>modafanil (generic PROVIGIL)</p> <p>NUVIGIL (armodafinil)</p>	<p>For beneficiaries with ADD/ADHD or narcolepsy warranting treatment with a stimulant or non-stimulant (either preferred or non-preferred), a diagnosis of ADD/ADHD or narcolepsy must be documented in the beneficiaries medical record at the time of diagnosis and annually.</p> <p>For patients with ADD/ADHD, prior to receiving pharmacotherapy, the beneficiary must have additional documentation through a validated ADHD/ADD instrument.</p> <p>For beneficiaries with ADD/ADHD who are currently receiving a stimulant or non-stimulant but does not have an official diagnosis of ADD/ADHD, the beneficiary will have six months to obtain a diagnosis otherwise the medication will be discontinued.</p> <p>Non-preferred agents will be approved for members who have documented failure with two Preferred products in the last 12 months (age six years or older) or documented failure with one Preferred products in the last 12 months if ages 3 – 5 years (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction). However, certain exceptions exist for Daytrana, Intuniv, Methylin solution, Quillivant XR, Nuvigil and Provigil. Please see the criteria below.</p> <p>In addition: Non-preferred agents will only be approved for FDA and official compendium indications.</p> <ul style="list-style-type: none"> ▪ Intuniv will be approved for members with a diagnosis of ADHD and ADD. Beneficiaries with ADD/ADHD must fail a 4 week trial of generic guanfacine before the use of Intuniv® will be approved. Only one tablet per day will be approved. ▪ Beginning 11/1/2013, Provigil will only be approved for Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Shift Work Sleep Disorder, Traumatic Brain Injury, Multiple Sclerosis related fatigue or ADHD. Beneficiaries must fail a 4 week trial of a Preferred Stimulant before the use of Provigil® will be approved. Only one tablet per day will be approved. ▪ Nuvigil will be approved for obstructive sleep apnea/hypopnea syndrome, narcolepsy and shift work sleep disorder. Beneficiaries with ADD/ADHD must fail a 4 week trial of a

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

		<p>PROCENTRA (dextroamphetamine liquid)</p> <p>PROVIGIL (modafinil)</p> <p>QUILLIVANT XR (methylphenidate)</p>	<p>Preferred Stimulant before the use of Nuvigil® will be approved. Only one tablet per day will be approved.</p> <ul style="list-style-type: none"> ▪ All other Non-preferred products will be approved for members with a diagnosis of ADD, ADHD, Narcolepsy, Multiple Sclerosis related fatigue, traumatic brain injury or severe autism. ▪ Daytrana, Methylin solution and Quillivant XR: Members with documented difficulty swallowing that are unable to utilize alternative dosing with FOCALIN XR, VYVANSE or ADDERALL XR can receive approval without failure on preferred products. Provider must document contraindications. <p>And</p> <p>Non-preferred agents will only be approved for FDA approved age limitations.</p> <ul style="list-style-type: none"> ▪ Provigil will be approved for members 16 years of age and older. ▪ Nuvigil will be approved for members 17 years of age and older. ▪ Adderall IR, Dexedrine and Dextrostat will be approved for members 3 years of age and older. ▪ All other medications in this class will be approved for members 6 years of age and older. <p>Regardless of the preferred/ non-preferred status, a PA will be required for patients who exceed the following maximum daily doses.</p> <table border="1" data-bbox="1157 1032 2045 1419"> <thead> <tr> <th data-bbox="1157 1032 1629 1068">Drug</th> <th data-bbox="1629 1032 2045 1068">Maximum Daily Dose</th> </tr> </thead> <tbody> <tr> <td data-bbox="1157 1068 1629 1101">ADDERALL ®</td> <td data-bbox="1629 1068 2045 1101">40 mg</td> </tr> <tr> <td data-bbox="1157 1101 1629 1133">ADDERALL XR®</td> <td data-bbox="1629 1101 2045 1133">40 mg</td> </tr> <tr> <td data-bbox="1157 1133 1629 1166">AMPHETAMINE SALTS</td> <td data-bbox="1629 1133 2045 1166">40 mg</td> </tr> <tr> <td data-bbox="1157 1166 1629 1198">CONCERTA ER ®</td> <td data-bbox="1629 1166 2045 1198">54 mg or 72 mg \geq age 13</td> </tr> <tr> <td data-bbox="1157 1198 1629 1230">D-AMPHETAMINE ER</td> <td data-bbox="1629 1198 2045 1230">40 mg</td> </tr> <tr> <td data-bbox="1157 1230 1629 1263">DAYTRANA ®</td> <td data-bbox="1629 1230 2045 1263">30 mg</td> </tr> <tr> <td data-bbox="1157 1263 1629 1295">DESOXYN ®</td> <td data-bbox="1629 1263 2045 1295">25 mg</td> </tr> <tr> <td data-bbox="1157 1295 1629 1328">DEXEDRINE ®</td> <td data-bbox="1629 1295 2045 1328">40 mg</td> </tr> <tr> <td data-bbox="1157 1328 1629 1360">DEXTROSTAT ®</td> <td data-bbox="1629 1328 2045 1360">40 mg</td> </tr> <tr> <td data-bbox="1157 1360 1629 1393">FOCALIN ®</td> <td data-bbox="1629 1360 2045 1393">20 mg</td> </tr> <tr> <td data-bbox="1157 1393 1629 1425">FOCALIN XR ®</td> <td data-bbox="1629 1393 2045 1425">40 mg</td> </tr> </tbody> </table>	Drug	Maximum Daily Dose	ADDERALL ®	40 mg	ADDERALL XR®	40 mg	AMPHETAMINE SALTS	40 mg	CONCERTA ER ®	54 mg or 72 mg \geq age 13	D-AMPHETAMINE ER	40 mg	DAYTRANA ®	30 mg	DESOXYN ®	25 mg	DEXEDRINE ®	40 mg	DEXTROSTAT ®	40 mg	FOCALIN ®	20 mg	FOCALIN XR ®	40 mg
Drug	Maximum Daily Dose																										
ADDERALL ®	40 mg																										
ADDERALL XR®	40 mg																										
AMPHETAMINE SALTS	40 mg																										
CONCERTA ER ®	54 mg or 72 mg \geq age 13																										
D-AMPHETAMINE ER	40 mg																										
DAYTRANA ®	30 mg																										
DESOXYN ®	25 mg																										
DEXEDRINE ®	40 mg																										
DEXTROSTAT ®	40 mg																										
FOCALIN ®	20 mg																										
FOCALIN XR ®	40 mg																										

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	---

			<table border="1"> <tbody> <tr><td>INTUNIV ER®</td><td>4 mg</td></tr> <tr><td>KAPVAY ER ®</td><td>0.1 mg</td></tr> <tr><td>METADATE CD ®</td><td>60 mg</td></tr> <tr><td>METHYLIN</td><td>60 mg</td></tr> <tr><td>METHYLIN ER ®</td><td>60 mg</td></tr> <tr><td>METHYLIN SUSPENSION®</td><td>60 mg</td></tr> <tr><td>METHYLPHENIDATE</td><td>60 mg</td></tr> <tr><td>METHYLPHENIDATE ER</td><td>60 mg</td></tr> <tr><td>METHYLPHENIDATE SR</td><td>60 mg</td></tr> <tr><td>NUVIGIL ®</td><td>250 mg</td></tr> <tr><td>PROVIGIL ®</td><td>400 mg</td></tr> <tr><td>QUILLIVANT XR ®</td><td>60 mg</td></tr> <tr><td>RITALIN LA ®</td><td>60 mg</td></tr> <tr><td>STRATTERA ®</td><td>The lesser of: 1.4mg/kg or 100 mg</td></tr> <tr><td>VYVANSE ®</td><td>70 mg</td></tr> </tbody> </table>	INTUNIV ER®	4 mg	KAPVAY ER ®	0.1 mg	METADATE CD ®	60 mg	METHYLIN	60 mg	METHYLIN ER ®	60 mg	METHYLIN SUSPENSION®	60 mg	METHYLPHENIDATE	60 mg	METHYLPHENIDATE ER	60 mg	METHYLPHENIDATE SR	60 mg	NUVIGIL ®	250 mg	PROVIGIL ®	400 mg	QUILLIVANT XR ®	60 mg	RITALIN LA ®	60 mg	STRATTERA ®	The lesser of: 1.4mg/kg or 100 mg	VYVANSE ®	70 mg
INTUNIV ER®	4 mg																																
KAPVAY ER ®	0.1 mg																																
METADATE CD ®	60 mg																																
METHYLIN	60 mg																																
METHYLIN ER ®	60 mg																																
METHYLIN SUSPENSION®	60 mg																																
METHYLPHENIDATE	60 mg																																
METHYLPHENIDATE ER	60 mg																																
METHYLPHENIDATE SR	60 mg																																
NUVIGIL ®	250 mg																																
PROVIGIL ®	400 mg																																
QUILLIVANT XR ®	60 mg																																
RITALIN LA ®	60 mg																																
STRATTERA ®	The lesser of: 1.4mg/kg or 100 mg																																
VYVANSE ®	70 mg																																
<p>TARGETED IMMUNE MODULATORS FOR RHEUMATOID ARTHRITIS</p> <p><i>Effective 1/1/2014</i></p>	<p>No PA Required</p> <p>ENBREL (etanercept)</p> <p>HUMIRA (adalimumab)</p>	<p>PA Required</p> <p>ACTEMRA (tocilizumab)</p> <p>CIMZIA (certolizumab)</p> <p>KINERET (anakinra)</p> <p>ORENCIA (abatacept) Subcutaneous</p> <p>SIMPONI (golimumab)</p> <p>STELARA (ustekinumab)</p> <p>XELJANZ (tofacitinib)</p> <p>*for information on IV infused Targeted Immune Modulators for Rheumatoid Arthritis please see Appendix P</p>	<p>Cimzia (all dosage forms)</p> <ul style="list-style-type: none"> will be approved for treatment of Crohn’s disease in members who have had treatment failure with Humira (Failure is defined as: lack of efficacy of a 3 month trial, allergy, intolerable side effects, or significant drug-drug interaction.) will be approved for treatment of RA in members who have had treatment failure with Enbrel and Humira (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction.) will be approved for treatment of Ankylosing Spondylitis or Psoriatic Arthritis in members who have had treatment failure with Enbrel and Humira (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction.) <p>Kineret will be approved for treatment of RA in members who have had treatment failure with Enbrel and Humira (Failure is defined as: lack of efficacy of a 3 month trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Kineret will be approved without PA for members with documented neonatal-onset multisystem inflammatory disease (NOMID).</p>																														

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
			<p>Orencia will be approved for the treatment of RA in members who have tried and failed Enbrel and Humira (Failure is defined as: lack of efficacy of a 3 month trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Simponi will be approved (in combination with methotrexate) for treatment of RA in members who have tried and failed Enbrel and Humira (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Simponi will be approved with or without methotrexate for the treatment of Ankylosing Spondylitis or Psoriatic Arthritis in members who have tried and failed Enbrel and Humira (Failure is defined as: lack of efficacy of a 3 month trial, allergy, intolerable side effects or significant drug-drug interaction).</p> <p>Simponi will be approved for treatment of ulcerative colitis in members who have tried and failed Humira (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Stelara will be approved with or without methotrexate for the treatment of Psoriatic Arthritis in members who have tried and failed Enbrel and Humira (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction.)</p> <p>Stelara will be approved for moderate to severe plaque psoriasis in members who have tried and failed Enbrel and Humira (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction.)</p> <p>Xeljanz will be approved for the treatment of RA in members who have had treatment failure with methotrexate with at least two separate preferred TNF inhibitors (Humira and Enbrel). (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction.)</p> <p>Xeljanz will be not be approved for combination therapy with a biologic disease modifying agent.</p>

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
------------------------	------------------	----------------------	--

			Quantity Limits: 2 tablets per day or 60 tablets for a 30 day supply Grandfathering: Members currently stabilized on a Non-preferred product can receive approval to continue on that agent for one year if medically necessary.
TESTOSTERONE PRODUCTS <i>Effective 7/1/2014</i>	No PA required (must meet criteria) ANDROGEL 1.62% (testosterone topical) ANDRODERM (testosterone patch) DEPO TESTOSTERONE ^{BNR} (testosterone injection)	PA Required ANDROGEL 1% AXIRON FORTESTA gel STRIANT TESTIM gel Testosterone Cypionate Testosterone Enanthate VOGELXO	Preferred androgenic drugs will be approved for members meeting the following: <i>Hypogonadotropic or Primary Hypogonadism</i> <ul style="list-style-type: none"> • Male patient ≥18 years of age • Has a documented diagnosis of hypogonadotropic or primary hypogonadism (Patients with other diagnoses will require a manual review by a state pharmacist) AND • Has two documented low serum testosterone levels below the lower limit of normal range for testing laboratory prior to initiation of therapy AND • Does not have a diagnosis of breast or prostate cancer AND • Does not have a palpable prostate nodule or prostate-specific antigen (PSA) >4ng/ml AND • Has normal liver function tests prior to initiation of therapy <i>Gender Transition</i> <ul style="list-style-type: none"> • Biologically born female patient ≥ 18 years of age* AND • Is undergoing female to male transition AND • Has a negative pregnancy test AND • Has normal liver function test prior to initiation of therapy *For members <18 years of age, a manual review will be required. Non preferred androgenic products will be approved for patients meeting the above criteria with documented failure with an 8 week trial of a preferred androgenic product. (Failure is defined as: lack of efficacy of a three month trial, allergy, intolerable side effects, or significant drug-drug interaction.)

Therapeutic Drug Class	Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred Products will be approved for one year unless otherwise stated.)
TOPICAL IMMUNOMODULATORS <i>Effective 7/1/2014</i>	No PA Required (must meet criteria) ELIDEL (pimecrolimus)*	PA Required PROTOPIC (tacrolimus)	<p>*Elidel will only be approved after a member has had an adequate trial (e.g., one month or longer) of a topical steroid and failed treatment. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). This will be a one-time PA.</p> <p>Protopic will only be approved for a member who had an adequate trial (e.g. one month or longer) of a topical steroid and Elidel and failed treatment. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). This will be a one-time PA.</p> <p>PA is required for children < 2 years of age.</p> <p>PA will be required for members warranting ≥ 6 weeks of therapy with either Elidel or Protopic.</p>
TRIPTANS <i>Effective 1/1/2014</i>	No PA Required (monthly quantity limits may apply) IMITREX (ondansetron) tablets IMITREX (ondansetron) nasal spray and injection <small>BNR</small> MAXALT MLT tablets (rizatriptan) naratriptan tablets sumatriptan tablets	PA Required AMERGE (naratriptan) AXERT (almotriptan) FROVA (frovatriptan) Maxalt tablets (rizatriptan) RELPAX (eletriptan) SUMAVEL DOSEPRO (sumatriptan) TREXIMET (sumatriptan and naproxen) sumatriptan nasal spray and injection ZOMIG (zolmitriptan)	<p>Non-preferred products will be approved for members who have failed treatment with two Preferred Products within the last 6 months. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions)</p> <p>Quantity Limits: Amerge, Frova, Imitrex, Treximet and Zomig: Max 9 tabs / 30 days. Axert and Relpax: Max 6 tabs / 30 days. Imitrex injection: Max 4 injectors / 30 days Maxalt: Max 12 tabs / 30 days. Zomig nasal spray and Imitrex Nasal Spray: Max 6 inhalers / 30 days.</p>